Ranitidine Hydrochloride

Ingredient matches for Ranitidine Hydrochloride

Ranitidine

Ranitidine Hydrochloride (BANM, JAN) is known as Ranitidine in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
JAN	Japanese Accepted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Amplium

Amplium may be available in the countries listed below.

Ingredient matches for Amplium

Ampicillin

Ampicillin sodium salt (a derivative of Ampicillin) is reported as an ingredient of Amplium in the following countries:

• Italy

Cloxacillin

Cloxacillin sodium salt (a derivative of Cloxacillin) is reported as an ingredient of Amplium in the following countries:

• Italy

Tinidazole

Tinidazole is reported as an ingredient of Amplium in the following countries:

• Brazil

International Drug Name Search

Carfentanil Citrate

Carfentanil Citrate may be available in the countries listed below.

Ingredient matches for Carfentanil Citrate

Carfentanil

Carfentanil Citrate (USAN) is also known as Carfentanil (Rec.INN)

International Drug Name Search

Glossary

Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Fluacet

Fluacet may be available in the countries listed below.

Ingredient matches for Fluacet

Fluocinolone

Fluocinolone Acetonide is reported as an ingredient of Fluacet in the following countries:

• Bosnia & Herzegowina


• Croatia (Hrvatska)


• Slovenia

International Drug Name Search

Keppra XR

See also: Generic Keppra

Keppra XR is a brand name of levetiracetam, approved by the FDA in the following formulation(s):

KEPPRA XR (levetiracetam - tablet, extended release; oral)

• 
  Manufacturer: UCB INC
  
  Approval date: September 12, 2008
  
  Strength(s): 500MG ^[AB]


• 
  Manufacturer: UCB INC
  
  Approval date: February 12, 2009
  
  Strength(s): 750MG ^[RLD][AB]

Has a generic version of Keppra XR been approved?

A generic version of Keppra XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Keppra XR and have been approved by the FDA:

levetiracetam tablet, extended release; oral

• 
  Manufacturer: ACTAVIS ELIZABETH
  
  Approval date: September 12, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: ANCHEN PHARMS
  
  Approval date: October 4, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: APOTEX INC
  
  Approval date: September 12, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: LUPIN LTD
  
  Approval date: September 12, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: MUTUAL PHARM CO INC
  
  Approval date: September 12, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: MYLAN PHARMS INC
  
  Approval date: December 19, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: PAR PHARM
  
  Approval date: September 12, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: September 12, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]


• 
  Manufacturer: WATSON LABS FLORIDA
  
  Approval date: September 12, 2011
  
  Strength(s): 500MG ^[AB], 750MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Keppra XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Extended release formulation of levetiracetam
  Patent 7,858,122
  Issued: December 28, 2010
  Inventor(s): Kshirsagar; Rajesh & Joshi; Mayank & Raichandani; Yogesh
  Assignee(s): UCB Pharma S.A.
  An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.
  
  Patent expiration dates:
  
  
  • September 17, 2028
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 12, 2011 - NEW DOSAGE FORM
  
  

See also...

• Keppra XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Keppra XR Consumer Information (Cerner Multum)
• Keppra XR Advanced Consumer Information (Micromedex)
• Levetiracetam Consumer Information (Wolters Kluwer)
• Levetiracetam Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Levetiracetam Solution Consumer Information (Wolters Kluwer)
• Levetiracetam Tablets Consumer Information (Wolters Kluwer)
• Levetiracetam Consumer Information (Cerner Multum)
• Levetiracetam Advanced Consumer Information (Micromedex)
• Levetiracetam Intravenous Advanced Consumer Information (Micromedex)
• Levetiracetam AHFS DI Monographs (ASHP)

Edemin

Edemin may be available in the countries listed below.

Ingredient matches for Edemin

Furosemide

Furosemide is reported as an ingredient of Edemin in the following countries:

• Indonesia

International Drug Name Search

Kaneuron

Kaneuron may be available in the countries listed below.

Ingredient matches for Kaneuron

Phenobarbital

Phenobarbital is reported as an ingredient of Kaneuron in the following countries:

• France


• Greece

International Drug Name Search

Amitriptyline-Lans

Amitriptyline-Lans may be available in the countries listed below.

Ingredient matches for Amitriptyline-Lans

Amitriptyline

Amitriptyline is reported as an ingredient of Amitriptyline-Lans in the following countries:

• Russian Federation

International Drug Name Search

Trofosfamide

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01AA07

CAS registry number (Chemical Abstracts Service)

0022089-22-1

Chemical Formula

C9-H18-Cl3-N2-O2-P

Molecular Weight

323

Therapeutic Category

Antineoplastic agent, alkylating agent

Chemical Name

2H-1,3,2-Oxazaphosphorin-2-amine, N,N,3-tris(2-chloroethyl)tetrahydro-, 2-oxide

Foreign Names

• Trofosfamidum (Latin)
• Trofosfamid (German)
• Trofosfamide (French)
• Trofosfamida (Spanish)

Generic Names

• Asta Z-4828 (IS: Asta)
• Trophosphamide (IS)
• Z 4828 (IS)

Brand Name

• Ixoten
  Baxter Oncology, Germany

International Drug Name Search

Glossary

IS	Inofficial Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.